To evaluate the possibility of administering therapeutic proteins via the respiratory route, we administered an aerosol ofrecombinant DNA-produced human a1-antitrypsin (rAAT) to anesthetized sheep and measured levels of the protein in epithelial lining fluid (ELF), lung lymph, blood, and urine.
tively. Importantly, evaluation with aerosolized 125I-labeled rAAT demonstrated that the rAAT molecules that reached the lung lymph and the systemic circulation remained intact as a 45-kDa protein. These results demonstrate the feasibility of using aerosolization to the pulmonary epithelial surface to administer sizeable proteins of therapeutic interest, thus circumventing the necessity of the traditional parenteral modes of administration of such molecules.
The development of recombinant DNA technologies has made available a variety of human proteins that have potential as therapeutic agents in the treatment of human disorders (1) (2) (3) (4) (5) (6) (7) (8) . However, in contrast to the relative ease of production of recombinant molecules, one serious obstacle to their use is that as proteins they are susceptible to proteolysis in the gastrointestinal tract and are not absorbed through the skin, thus necessitating that they be administered by a subcutaneous, intramuscular, or intravenous route (1) (2) (3) (4) (5) (6) (7) (8) . This is not a problem for proteins used therapeutically only in acute situations such as tissue plasminogen activator (8) , but it markedly complicates the use of recombinant proteins in the repetitive treatment of chronic disease. For example, recombinant growth hormone and insulin are routinely administered by the subcutaneous route (6, 7) , and studies with recombinant interferon-'y, interferon-a, and granulocytemonocyte colony-stimulating factor, erythropoietin, and interleukin 2 have necessitated subcutaneous, intramuscular, or intravenous routes of administration (1-5, 9, 10) .
As an alternative approach to administration ofrecombinant proteins (and proteins in general, independent of the source), the present study was designed to capitalize on the enormous surface area of the lung as a potential absorptive surface through which proteins of therapeutic importance could gain access to the interstitium of the lung and plasma while remaining intact. This concept is based on the knowledge that (i) droplets of 3-,um diameter inhaled as an aerosol have the potential to reach the alveolar surface (11) (12) (13) (14) ; (ii) the epithelial surface of the human lower respiratory tract is very large, typically 140 m2 in adults (15) ; (iii) plasma proteins as large as 100 kDa are found in the epithelial lining fluid surface of the lung, suggesting that proteins can diffuse across the capillary endothelium, the alveolar interstitium, and the alveolar epithelium (16) (17) (18) (19) ; and (iv) although there are no quantitative data available relating to the measurement of autologous natural or recombinant proteins from lower respiratory tract epithelial lining fluid to plasma, it is known that when solutions of heterologous proteins are instilled in the trachea of experimental animals, the protein can be subsequently detected in the pulmonary interstitium and blood (20) (21) (22) .
As a model to evaluate the possibility of using the lower respiratory tract to administer proteins of therapeutic interest, we have examined the pulmonary absorption of an aerosol of yeast-produced human recombinant a1-antitrypsin (rAAT), a 45-kDa single-chain polypeptide that functions as an inhibitor of neutrophil elastase (23) . To evaluate the absorption of the molecule, we have used sheep, an experimental animal in which the pulmonary lymphatics can be sampled, thus permitting quantification of protein levels in the fluid of the alveolar interstitium, the first compartment that would be encountered by a protein moving from the epithelial lining fluid across thealveolar epithelial surface (20, 21) . Using an aerosol generator capable of developing aerosol droplets of <3 jAm, the data clearly demonstrate that aerosolized rAAT deposited on the epithelial surface diffuses across the alveolar epithelial surface, reaches lung lymph and eventually the blood, and remains intact in the process.
METHODS
rAAT Preparation. The rAAT used in these studies was produced by yeast transformed with an expressing plasmid containing a human cDNA encoding the mature normal Ml (Val213) human a1-antitrypsin protein (23) (24) (25) . The expressing plasmid pFATPOT was transformed into a Saccharomyces cerevisiae strain to yield zymosan-3, a diploid yeast strain containing the pFATPOT construct (Cooper Laboratories) (23) . The rAAT was recovered from lysates of zymosan-3 and purified by sequential ion-exchange, affinity, and size-exclusion chromatography. The Aerosol-Generating System. To optimize the delivery of aerosolized rAAT to the lower respiratory tract, a nebulizer was used that maximized the generation of aerosol droplets in the <3-gm aerodynamic diameter range, a particle size appropriate for deposition in the alveolar regions (11) (12) (13) (14) . To accomplish this, 4 ml of a solution of rAAT at 25 mg/ml in physiologic saline (final osmolarity, 286 mosM) was placed in the reservoir of an Ultravent nebulizer (Mallinckrodt), which was driven at 40 psi (1 psi = 6.9 kPa) with compressed air. Evaluation of the aerosol by laser particle analyses carried out by S. P. Newman To evaluate the possible effects of aerosolization on the overall structure and function of rAAT, the rAAT aerosol was collected by bubbling the nebulizer output through phosphate-buffered saline (pH 7.4), and the resultant fluid was concentrated by pressure filtration (UM10 membrane, Amicon). To evaluate the effect of aerosol on the structure of rAAT, pre-and postaerosol samples were applied to a 10% SDS/polyacrylamide gel, and the protein bands were stained with Coomassie blue. To evaluate the effect of aerosol on the function of rAAT, the Ka for human neutrophil elastase of pre-and postaerosol rAAT was measured by the method of Beatty et al. (26) with minor modifications of Ogushi et al. (27) .
Experimental Model. Female mixed breed sheep (n = 15; 36 + 3 kg) were used to quantitate the levels of rAAT in the lung interstitium, lung epithelial lining fluid (ELF), blood, and urine following aerosolization of the rAAT. The sheep were anesthetized with intravenous sodium thiopental, and the trachea was intubated with a cuffed endotracheal tube attached to a positive pressure ventilator. Animals were ventilated at a tidal volume of 12 mllkg with 5 cm of H20 positive end expiratory pressure at a rate of 16 per min. Anesthesia was maintained with 1.0-1.5% fluothane, 50% nitrous oxide, and 50% oxygen. Lung lymph was collected from the caudal efferent lymphatic duct cannulated with a heparinized silastic catheter by the technique of Staub et al. (28) . Bronchoalveolar lavage fluid was obtained by lavage through a fiberoptic bronchoscope (Olympus) using a single 50-ml aliquot of normal saline. Blood samples were obtained from an indwelling catheter in the carotid artery, and urine samples were obtained from an in-dwelling bladder catheter.
All studies with the rAAT aerosol were performed with the closed chest animal in the prone position. After baseline bronchoalveolar lavage fluid, blood, lung lymph, and urine samples were obtained, 100 mg of rAAT was administered by aerosol into the inspiratory limb of the ventilation circuit over a 25-min period. Bronchoalveolar The creation of the rAAT aerosol with the compressed air-driven nebulizer did not alter the structure of rAAT or its ability to inhibit human neutrophil elastase (Fig. 1) . After aerosolization, the rAAT remained as an intact 45-kDa protein (Fig. 1A) . Importantly, the aerosolization process had no effect on the Ka of rAAT for human neutrophil elastase (P > 0.2, pre-vs. postaerosol) (Fig. 1B) .
Pharmacokinetics Lung lymph rAAT concentrations lagged significantly behind ELF concentrations; the peak lymph concentration occurred 12 hr after aerosolization. After 2 hr, lung lymph rAAT concentrations were -10 times less than the corresponding ELF rAAT concentration. By 48 hr postaerosol, small amounts of rAAT were still detectable in lung lymph even though no rAAT was found in ELF. Summation over the 48-hr period of the total rAAT recovered in lung lymph demonstrated 0.17% ± 0.02% of the total aerosolized dose:
Blood plasma levels of rAAT followed a time course similar to the lung lymph levels. On average, the plasma rAAT concentrations were -10% that of the lymph levels. Assuming a sheep total plasma volume of 3.6% body weight (30) , at 12 hr (the time of maximal plasma concentration), the total rAAT in plasma was -0.25% of the total aerosolized dose. In urine, rAAT was just at the detection limits of the assay (>1 ng/ml) at 12 and 24 hr; no rAAT was measured in the urine at any other time. Together, these data indicate that a portion of the aerosolized rAAT molecules must have been deposited in the lower respiratory tract, then passed across the alveolar epithelium into the alveolar interstitium and entered lung lymph, and ultimately reached the systemic circulation.
Form of rAAT in Lymph and Blood. After aerosol administration, not only did some of the rAAT molecules move across the epithelium to lymph and blood, but the molecules remained intact in the process (Fig. 3) cDNA-directed yeast-produced rAAT administered by aerosol to sheep. The data demonstrate that it is feasible to generate an aerosol that delivers significant quantities of intact functional rAAT to the alveolar surface and that, once deposited there, at least some of the protein diffuses from the alveolar surface to the lung interstitium and ultimately to the systemic circulation. Importantly, the aerosol process did not alter the form and function of the rAAT molecules, and the rAAT molecules did not undergo degradation during the process of deposition onto the alveolar epithelium and passage into the lung interstitium and the circulation. In this regard, these observations are significant for potential use of the aerosol route to administer proteins of therapeutic importance outside of the lung (e.g., insulin, growth hormone, hematologic growth factors, clotting factors) and for the therapy of pulmonary disorders, such as the potential use of rAAT for the specific therapy of the human hereditary disorder a1-antitrypsin deficiency.
The Lower Respiratory Tract as a Site for Administration of Therapeutic Proteins. Delivery of proteins to the alveolar surface requires that several physiologic obstacles be overcome, including the tortuosity of the upper air passages and the arborization of the bronchial tree, features that lead to substantial deposition of inhaled substances in the pharynx and proximal large airways, rather than in the alveoli (11) (12) (13) (14) . To maximize alveolar deposition, aerosol particles of -3 ,um or less must be inhaled; particles of this size are sufficiently small to avoid inertial impaction at airway branch points and do not undergo significant gravitational settling (11) (12) (13) .
However, not all sizes below 3 Am can be used; while particles 0.5 to 3 ,m are generally retained in the lung, particles <0.5 ,m may escape pulmonary deposition entirely and leave the lung in expired air (12, 13) .
We circumvented the natural physiologic obstacles against lower respiratory tract deposition by using a nebulizer capable of transforming a solution of rAAT into aerosol droplets, 55% of which were <3 ,m, and because of the narrow droplet size distribution, most droplets were between 0.5 and 3 ,um. In addition, use of an endotracheal tube for airway control and ventilation of the anesthetized animal likely contributed to the delivery of aerosolized rAAT to the lower respiratory tract. Importantly, the rAAT remained intact and completely functional after aerosolization, despite the fact that the active inhibitor site of a1-antitrypsin is easily oxidizable, and, when oxidized, the function of the a1-antitrypsin as an inhibitor of neutrophil elastase is reduced by a factor of 2000 (26) . Furthermore, the mass of rAAT that can be aerosolized in this fashion is considerable. In this regard, 100 mg of rAAT was aerosolized within 25 min, a total amount that is likely within the range necessary for potential therapeutic applications and in a time reasonable for chronic administration on a daily basis.
Once delivered to the epithelial surface, the protein must gain access to the interstitium of the alveoli (for proteins destined for local therapy) and the blood (for proteins to act in the blood or in distant organs). The present study clearly demonstrates rAAT passes from the alveolar ELF to lymph and to blood, entering the bloodstream either directly via diffusion of rAAT into alveolar capillaries or by drainage of lung lymph into the venous system. Thus, a relatively large plasma protein can move in a direction opposite that thought to be its normal physiologic path, and the molecule remains intact in the process. Our data do not give insight into how this occurs, but it could occur with endocytic and/or cell junction permeability processes (20, 21, (31) (32) (33) (34) and could be related, in part, to the fact that the rAAT is not glycosylated, in contrast to plasma a1-antitrypsin that contains three asparaginyl-linked complex carbohydrates (23, 24) . Consistent with our observations, there are several lines of evidence that the pulmonary "alveolar-capillary" barrier is permeable for proteins of considerable size.
First, morphologic and bronchoalveolar lavage studies have demonstrated intact plasma proteins in the ELF of the lower respiratory tract of experimental animals and humans (16) (17) (18) (19) 31) . The relative amount of these proteins in ELF in relation to their concentrations in plasma is dependent primarily on the molecular mass of the protein. In this regard, proteins in the 50-to 70-kDa range (such as albumin and a1-antitrypsin) have an ELF concentration -10% that in plasma, while proteins in the 80-to 230-kDa range (such as hemopexin and ceruloplasmin) have concentrations in ELF 5-10% of their plasma concentration, thus indicating some sieving by the lung epithelial barrier in this molecular mass range. Consistent with this concept, very large proteins, such as a2-macroglobulin (820 kDa) and IgM (900 kDa), are present in ELF in very low concentrations (16) (17) (18) (19) 35) .
Second, when proteins are infused intravenously to experimental animals, they are readily detected in lung lymph and ELF (20, 21, 28, 30, 36) . Furthermore, when a1-antitrypsin is infused intravenously to humans, the a1-antitrypsin is readily detectable in the lower respiratory tract ELF at levels -15% that achieved in plasma (37) . Likewise, when rAAT is infused into primates, the rAAT is readily detectable in lung ELF (23) .
Third, when solutions of heterologous proteins are directly instilled into the tracheobronchial tree of experimental animals, some of these proteins can be detected in lung interstitial fluid and in plasma (20) (21) (22) 38) . In addition, an aerosol of a nonautologous insulin to diabetic individuals resulted in lowering of blood glucose (39) , suggesting that at least some protein with a molecular mass of 5 kDa can pass from the alveolar epithelium to blood and remain functionally intact in the process.
There are clear differences between the alveolar epithelial and endothelial "barriers" in the lung, with the epithelial barrier being much the tighter. It is estimated that the overall air-to-blood permeability of the lower respiratory tract to albumin, a protein with the same mass range as rAAT, is -2 x 10-9 cm/sec, with '90% of the total resistance to flow due to the epithelial barrier (21, 30) . In accordance with this restricted permeability, -95% of radiolabeled albumin instilled directly into localized areas of the tracheobronchial tree in sheep remains in the lung at 4 hr and is slowly cleared into lymph (21) . These observations are consistent with those of the current study, in which rAAT aerosolized into the entire sheep lower respiratory tract also leaves the alveolar surface gradually, and with studies of aerosolized human plasma a1-antitrypsin to individuals with a1-antitrypsin deficiency, demonstrating that twice daily administration of 100 mg of a1-antitrypsin leads to increasing levels of a1-antitrypsin in lower respiratory tract ELF (40) . Thus, the epithelial surface of the lower respiratory tract is permeable to proteins like rAAT, but slowly. In this regard, the epithelial surface of the lower respiratory tract may serve as a "depot" that functions to slowly release proteins deposited by aerosol into the body-i.e., this natural epithelial "barrier" may serve as the equivalent of sustained slow release of the therapeutic protein to the body.
When compared to other epithelial surfaces, the lower respiratory tract has several characteristics that may be advantageous for drug administration. It has a vastly larger surface area (and thus a much larger potential absorptive surface) compared to the nasal, buccal, or rectal surfaces, sites that have been evaluated for administration of proteins (41, 42) . In this regard, the use of the lower respiratory tract may obviate the need to augment absorption per unit area, as has been suggested for the nasal epithelium using absorption enhancers such as bile salts, surfactants, or acrylic resins (43) (44) (45) . Furthermore, unlike the gastrointestinal tract, the lower respiratory tract surface is not a hostile environment to proteins. The lung does not normally contain large quantities of proteolytic enzymes and normally has an adequate antiprotease defensive screen (46) , so that most administered proteins should be able to survive in the lower respiratory tract intact with their bioactivity maintained.
Aerosolization of rAAT for the Therapy of a1-Antitrypsin Deficiency. a1-Antitrypsin deficiency is a hereditary disorder associated with low serum and lung levels of a1-antitrypsin, a molecule that normally protects the lower respiratory tract from neutrophil elastase, an omnivorous protease capable of degrading the matrix proteins comprising the alveolar interstitium (37, 47, 48) . As a consequence of this deficiency state, the lung has an insufficient protective screen against neutrophil elastase, leading to gradual relentless destruction of lung. Although the deficiency of a1-antitrypsin is systemic, since the lungs are the major site of the pathologic consequences of this hereditary disease in adults, direct targeting of a1-antitrypsin to the lung is a rational form of treatment. In this regard, while weekly intravenous augmentation therapy for a1-antitrypsin deficiency with human plasma-purified a1-antitrypsin is biochemically efficacious (i.e., it augments lung a1-antitrypsin levels adequate to protect the lung from accelerated destruction), it is inefficient because only -2% of the total administered dose actually reaches the lungs (37) .
Although rAAT functions as well as plasma-derived a1-antitrypsin as an inhibitor of neutrophil elastase, the rAAT has no carbohydrate side chains (23) . As a result, rAAT undergoes rapid renal clearance when administered intravenously and, consequently, has a very short serum half-life, thus obviating the intravenous route for the chronic administration of rAAT for a1-antitrypsin deficiency (23) . In contrast, aerosol administration of rAAT would permit direct targeting of the rAAT to the site where it is needed and in doing so would avoid the problem ofrapid renal excretion and would be highly efficient, with less waste of the administered protein. In this regard, the demonstration that rAAT administered by aerosol penetrates the lung epithelial surface and enters lung lymph supports this concept-i.e., the rAAT would be available to inhibit neutrophil elastase within the lung interstitium, thereby protecting alveolar interstitial connective tissue proteins from neutrophil elastase-mediated degradation.
In the context of these considerations, aerosol administration of rAAT may represent an ideal approach to therapy of a1-antitrypsin. However, to achieve this goal, it will be necessary to demonstrate that enough rAAT can be delivered to the lower respiratory tract such that sufficient rAAT reaches the alveolar interstitium to adequately raise the anti-neutrophil elastase defenses to protect the lung from chronic proteolytic attack. In the present study, -1/5OOth of the administered dose was recoverable in the lung lymph, a value likely too low to provide adequate protection for a1-antitrypsin deficiency. However, this is likely a significant underestimate of the amount that would be delivered to the alveolar interstitium during actual aerosol therapy since (i) only a portion of the total lung lymph flow was recovered; (ii) at least as much rAAT was already present in plasma by 12 hr; (iii) only a single dose was given, in contrast to the chronic aerosol administration that would actually be used for therapy; and (iv) the actual amount of rAAT delivered to the lower respiratory tract is less than the administered dose, due to unavoidable loss of some aerosolized rAAT on various surfaces of the ventilatory apparatus. Unfortunately, for a number of technical considerations and because the human rAAT is viewed as antigenic by experimental animals (49), chronic experimental aerosol studies are not possible. In this regard, evaluation of the feasibility of achieving the necessary therapeutic lung levels of anti-neutrophil elastase protection will have to await human studies with rAAT aerosol therapy.
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